InspireMD Inc

For the period ended Jun 30, 2024. Filed Aug 5, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 5, 2024

NSPR$0.71+2.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Equity

Common stock · Series C Convertible Preferred Stock · Additional paid-in · Accumulated · Total
	Shares	Amount	Shares	Amount	capital	deficit	equity
BALANCE AT January 1, 2023	8,330,918	1	1,718	-*	218,977	(201,585)	17,393
Net loss			-			(9,333)	(9,333)
Issuance of common shares, pre-funded warrants and warrants, net of $4,635 issuance costs	10,266,270	1		-	37,533	-	37,534
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 4,270 shares	2,595,016	-*		-	1,219	-	1,219
BALANCE AT June 30, 2023	21,192,204	2	1,718	-*	257,729	(210,918)	46,813

*	Represents an amount less than $1 thousand

Common stock · Series C Convertible Preferred Stock · Additional paid-in · Accumulated · Total
	Shares	Amount	Shares	Amount	capital	deficit	equity
BALANCE AT April 1, 2023	8,326,648	1	1,718	-*	219,266	(205,841)	13,426
Net loss			-			(5,077)	(5,077)
Issuance of common shares, pre-funded warrants and warrants, net of $4,635 issuance costs	10,266,270	1	-	-	37,533	-	37,534
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award	2,599,286	-*	-	-	930	-	930
BALANCE AT June 30, 2023	21,192,204	2	1,718	-*	257,729	(210,918)	46,813

*	Represents an amount less than $1 thousand

Common stock · Series C Convertible Preferred Stock · Additional paid-in · Accumulated · Total
	Shares	Amount	Shares	Amount	capital	deficit	equity
BALANCE AT January 1, 2024	21,841,215	2	1,718	-*	261,000	(221,501)	39,501
Net loss			-			(14,941)	(14,941)
Exercise of pre-funded warrants	1,528,390	-*	-	-	-	-	-*
Exercise of Warrants Series H to 12,621,090 pre-funded warrants and 292,996 common stock, net of $1,000 issuance costs	292,996	1	-	-	16,853	-	16,854
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures of 112,382 shares	1,533,878	-*	-	-	5,349	-	5,349
BALANCE AT June 30, 2024	25,196,479	3	1,718	-*	283,202	(236,442)	46,763

*	Represents an amount less than $1 thousand

Common stock · Series C Convertible Preferred Stock · Additional paid-in · Accumulated · Total
	Shares	Amount	Shares	Amount	capital	deficit	equity
BALANCE AT April 1, 2024	23,412,385	2	1,718	-*	263,618	(228,533)	35,087
Net loss			-			(7,909)	(7,909)
Exercise of pre-funded warrants	1,528,390	-*	-	-	-	-	-*
Exercise of Warrants Series H to 12,621,090 pre-funded warrants and 292,996 common stock, net of $1,000 issuance costs	292,996	1	-	-	16,853	-	16,854
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures of 37,292 shares	(37,292)	-*	-	-	2,731	-	2,731
BALANCE AT June 30, 2024	25,196,479	3	1,718	-*	283,202	(236,442)	46,763

*	Represents an amount less than $1 thousand

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.